Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing from hippocampal total lysates of the rTg4510 tauopathy mouse model.

ABSTRACT: RNA sequencing from hippocampal total lysates of the rTg4510 tauopathy mouse model.

PROVIDER: PRJNA772726 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16483000_1.fastq.gz	Fastqsanger.gz
	SRR16483000_2.fastq.gz	Fastqsanger.gz
	SRR16483001_1.fastq.gz	Fastqsanger.gz
	SRR16483001_2.fastq.gz	Fastqsanger.gz
	SRR16483002_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 70

Similar Datasets

RNA sequencing from hippocampal total lysates of the rTg4510 tauopathy mouse model.

Project description:RNA seqeuncing was perfomed to compare transcriptomic profiles of rTg4510 and control at three, six and nine month time points.

2021-10-21 | GSE186140 | GEO

RNA sequencing of total RNA from spinal cord total lysates of the PS19 tauopathy mouse model.

Project description:RNA sequencing of total RNA from spinal cord total lysates of the PS19 tauopathy mouse model.

| PRJNA773047 | ENA

The reverse transcriptase inhibitor 3TC modulates hippocampal transcriptome signatures of inflammation in tauopathy model mice

Project description:Reducing neuroinflammation, a main hallmark of brain aging and neurodegenerative diseases, is a promising strategy for improving cognitive function in these settings. The nucleoside reverse transcriptase inhibitor 3TC (Lamivudine) has been reported to improve cognitive function in old wild-type mice and in multiple mouse models of neurodegenerative disease, but the underlying mechanisms have not been comprehensively investigated. In the current study, we used transcriptomics to broadly characterize the effects of long-term supplementation with a human-equivalent therapeutic dose of 3TC on the hippocampal transcriptome in male and female rTg4510 mice (a commonly studied model of tauopathy-associated neurodegeneration). We found that tauopathy increased hippocampal transcriptomic signatures of neuroinflammation/immune activation, but 3TC treatment reversed many of these transcriptome changes. We also found that 3TC mitigated tauopathy-associated activation of several key transcription factors that contribute to neuroinflammation and immune activation, and several of these changes were correlated with improved recognition memory performance.Our findings suggest that 3TC exerts beneficial effects on the hippocampus in the context of tauopathy by modulating pathways associated with inflammation and immune response.

2024-05-13 | GSE243650 | GEO

RNA changes in hippocampus of transgenic murine model of tauopathy (rTg4510 mice) compared to controls at asymptomatic stage (2 months) of neurodegeneration as determined by mRNA deep sequencing.

Project description:The overall goal of the project is to assess the mRNA alterations in tauopathy conditions that occur at the presymptomatic stage of neurodegeneration. The animal model selected for this study is a well characterized tauopathy animal model, known as rTg4510 murine model. rTg4510 (tau) is a transgenic mouse model of human tauopathy expressing human tau containing the P301L mutation that is associated with familial frontotemporal dementia and parkinsonism linked to chromosome 17. The expression of P301L tau driven by CaMKII promoter peaks around two month-of-age and mainly in the forebrain. 2-month of age is considered the presymptomatic stage of neurodegeneration. The global expression of mRNAs was evaluated by mRNA deep sequencing in the hippocampus of tau mice at 2 months of age. The levels of several mRNAs were altered in the hippocampus of tau mice at 2 months. Many important candidates were further evaluated for their molecular and functional contributions to the process of neurodegeneration.

2018-07-24 | GSE107183 | GEO

Small RNA changes in hippocampus of transgenic murine model of tauopathy (rTg4510 mice) compared to littermate controls at asymptomatic stage (2 months) of neurodegeneration as determined by small RNA deep sequencing.

Project description:The overall goal of the project is to assess whether small RNA, especially microRNA (miR) alterations in tauopathy conditions contribute to pathological changes that later lead to neurodegeneration. The animal model selected for this study is a well characterized tauopathy animal model, known as rTg4510 murine model. rTg4510 (tau) is a transgenic mouse model of human tauopathy expressing human tau containing the P301L mutation that is associated with familial frontotemporal dementia and parkinsonism linked to chromosome 17. The expression of P301L tau driven by CaMKII promoter peaks around two month-of-age and mainly in the forebrain. 2-month of age is considered the asymptomatic stage of neurodegeneration. The global expression of miRs was evaluated by small RNA sequencing in the hippocampus of tau mice at 2 months of age. The levels of several miRs were altered in the hippocampus of tau mice at 2 months. Many important candidates were further evaluated for their molecular and functional contributions to the process of neurodegeneration.

2018-07-24 | GSE106945 | GEO

Small RNA changes in hippocampus of transgenic murine model of tauopathy (rTg4510 mice) compared to littermate controls at symptomatic stage (6 months) of neurodegeneration as determined by small RNA deep sequencing.

Project description:The overall goal of the project is to assess whether small RNA, especially microRNA (miR) alterations in tauopathy conditions contribute to pathological changes that later lead to neurodegeneration. The animal model selected for this study is a well characterized tauopathy animal model, known as rTg4510 murine model. rTg4510 (tau) is a transgenic mouse model of human tauopathy expressing human tau containing the P301L mutation that is associated with familial frontotemporal dementia and parkinsonism linked to chromosome 17. The expression of P301L tau driven by CaMKII promoter peaks around two month-of-age and mainly in the forebrain. 6-month of age is considered the aymptomatic stage of neurodegeneration. The global expression of miRs was evaluated by small RNA sequencing in the hippocampus of tau mice at 6 months of age. The levels of several miRs were altered in the hippocampus of tau mice at 6 months which were compared to deep sequencing data from 2-month of age. Many important candidates were further evaluated for their molecular and functional contributions to the process of neurodegeneration.

2018-07-24 | GSE106946 | GEO

Age-dependent gene expression in the hippocampus of rTg4510 mice

2014-06-14 | GSE56772 | GEO

Age-dependent gene expression in the hippocampus of rTg4510 mice

Project description:Microarrays were used to assess the adult hippocampal gene expression patterns in the rTg4510 mouse line at various ages. This line harbors a repressible mutant human Tau transgene under the Camk2a promoter. Both mice with just the tet-Transactivator alone and no transgenes ('double negative') were used as comparison groups. Hippocampi from (1-4) mice per genotype at ages ranging from 1.7 to 10.8 months of age were dissected, RNA isolated, and hybridization to Affymetrix microarrays performed.

2014-06-14 | E-GEOD-56772 | biostudies-arrayexpress

Gene expression in hippocampal sub-fields of 6.1 month old rTg4510 mice

Project description:Microarrays were used to assess the gene expression patterns in the CA1, CA3, and dentate gyrus of the rTg4510 mouse line at 6.1 months of age. This line harbors a repressible mutant human Tau transgene under the Camk2a promoter. Both mice with just the tet-Transactivator alone and no transgenes ('double negative') were used as comparison groups.

2014-06-14 | GSE57583 | GEO

Gene expression in hippocampal sub-fields of 4.5 month old rTg4510 mice

Project description:Microarrays were used to assess the gene expression patterns in the CA1, CA3, and dentate gyrus of the rTg4510 mouse line at 4.5 months of age. This line harbors a repressible mutant human Tau transgene under the Camk2a promoter. Both mice with just the tet-Transactivator alone and no transgenes ('double negative') were used as comparison groups.

2014-06-14 | GSE57528 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data